Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2023 Mar 15;133(6):e170315. doi: 10.1172/JCI170315

CDK4 is an essential insulin effector in adipocytes

Sylviane Lagarrigue, Isabel C Lopez-Mejia, Pierre-Damien Denechaud, Xavier Escoté, Judit Castillo-Armengol, Veronica Jimenez, Carine Chavey, Albert Giralt, Qiuwen Lai, Lianjun Zhang, Laia Martinez-Carreres, Brigitte Delacuisine, Jean-Sébastien Annicotte, Emilie Blanchet, Sébastien Huré, Anna Abella, Francisco J Tinahones, Joan Vendrell, Pierre Dubus, Fatima Bosch, C Ronald Kahn, Lluis Fajas
PMCID: PMC10014095  PMID: 36919703

Original citation: J Clin Invest. 2016;126(1):335–348. https://doi.org/10.1172/JCI81480

Citation for this retraction: J Clin Invest. 2023;133(6):170315. https://doi.org/10.1172/JCI170315

At the request of the corresponding author, the JCI is retracting this article. The authors became aware that the genotype of the mice described as Cdk4neo/neo Rip-Cre was incorrect. The correct mouse genotype was Cdk4neo/neo Rip-Cdk4R24C. The model used transgenically expresses the Cdk4R24C allele under the control of the rat insulin promoter (Rip-Cdk4R24C) rather than expressing Cdk4R24C in the Cdk4 locus as described in the article. Due to this unintentional error, the corresponding author requested retraction.

Version 1. 03/15/2023

Electronic publication

Footnotes


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES